Goldman Sachs Group Inc Cardiol Therapeutics Inc. Transaction History
Goldman Sachs Group Inc
- $605 Billion
- Q3 2024
A detailed history of Goldman Sachs Group Inc transactions in Cardiol Therapeutics Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 36,100 shares of CRDL stock, worth $46,208. This represents 0.0% of its overall portfolio holdings.
Number of Shares
36,100
Previous 23,500
53.62%
Holding current value
$46,208
Previous $47,000
51.06%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding CRDL
# of Institutions
45Shares Held
5.07MCall Options Held
5.2KPut Options Held
9.5K-
Tejara Capital LTD London, X01.77MShares$2.27 Million1.67% of portfolio
-
Advisor Shares Investments LLC Bethesda, MD1.17MShares$1.5 Million0.46% of portfolio
-
Mmcap International Inc. Spc Grand Cayman, E9796KShares$1.02 Million0.36% of portfolio
-
Lion Street Advisors, LLC273KShares$349,7990.19% of portfolio
-
Foundations Investment Advisors, LLC162KShares$207,2960.01% of portfolio
About Cardiol Therapeutics Inc.
- Ticker CRDL
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 61,942,500
- Market Cap $79.3M
- Description
- Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate t...